Presidio Pharmaceuticals, Inc. Selects PPI-461 as a Clinical Candidate in Their Hepatitis C Virus NS5A Program

July 7, 2009 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

SAN FRANCISCO--(BUSINESS WIRE)--Presidio Pharmaceuticals, Inc. announced today that they have selected one of the lead compounds in their hepatitis C virus (HCV) NS5A program to advance toward clinical development.

Twitter
LinkedIn
Facebook
Email
Print